FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323036081> ?p ?o ?g. }

• W4323036081 endingPage "2218" @default.
• W4323036081 startingPage "2210" @default.
• W4323036081 abstract "225Ac-PSMA-617 has demonstrated good anti-tumor effect as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients. No study has previously assessed treatment outcome and survival following 225Ac-PSMA-617 treatment of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC) patients. Based on the potential side effects that are known and explained to the patients by the oncologist, some of the patients refused the standard treatment and are seeking alternative therapies. Thus, we report our preliminary findings in a retrospective series of 21 mHSPC patients that refused standard treatment options and were treated with 225Ac-PSMA-617.We retrospectively reviewed patients with histologically confirmed de novo treatment-naïve bone ± visceral mHSPC that were treated with 225Ac-PSMA-617 radioligand therapy (RLT). Inclusion criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, treatment-naive bone ± visceral mHSPC, and patients refusal for ADT ± docetaxel, abiraterone acetate, or enzalutamide. We evaluated the response to treatment using prostate-specific antigen (PSA) response and the progression-free survival (PFS) and overall survival (OS) as well as the toxicities.Twenty-one mHSPC patients were included in this preliminary work. Following treatment, twenty patients (95%) had any decline in PSA and eighteen patients (86%) presented with a PSA decline of ≥ 50% including 4 patients in whom PSA became undetectable. A lower percentage decrease in PSA following treatment was associated with increased mortality and shorter progression-free survival. Overall, administration of 225Ac-PSMA-617 was well tolerated. The commonest toxicity seen was grade I/II dry mouth observed in 94% of patients.Given these favorable results, randomized prospective multicenter trials assessing the clinical value of 225Ac-PSMA-617 as a therapeutic agent for mHSPC administered either as monotherapy or administered concomitant with ADT are of interest." @default.
• W4323036081 created "2023-03-04" @default.
• W4323036081 creator A5008293723 @default.
• W4323036081 creator A5010463928 @default.
• W4323036081 creator A5029014575 @default.
• W4323036081 creator A5035484134 @default.
• W4323036081 creator A5045912194 @default.
• W4323036081 creator A5048456616 @default.
• W4323036081 creator A5050744570 @default.
• W4323036081 creator A5057397331 @default.
• W4323036081 creator A5063488694 @default.
• W4323036081 creator A5066767510 @default.
• W4323036081 creator A5067342192 @default.
• W4323036081 creator A5070642253 @default.
• W4323036081 date "2023-03-03" @default.
• W4323036081 modified "2023-09-27" @default.
• W4323036081 title "225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings" @default.
• W4323036081 cites W1542081224 @default.
• W4323036081 cites W2085332968 @default.
• W4323036081 cites W2100423100 @default.
• W4323036081 cites W2137605045 @default.
• W4323036081 cites W2142466432 @default.
• W4323036081 cites W2150865892 @default.
• W4323036081 cites W2214621962 @default.
• W4323036081 cites W2278392405 @default.
• W4323036081 cites W2341130139 @default.
• W4323036081 cites W2606187374 @default.
• W4323036081 cites W2620746860 @default.
• W4323036081 cites W2728713011 @default.
• W4323036081 cites W2767249739 @default.
• W4323036081 cites W2782678772 @default.
• W4323036081 cites W2784080506 @default.
• W4323036081 cites W2800823189 @default.
• W4323036081 cites W2809795864 @default.
• W4323036081 cites W2885727665 @default.
• W4323036081 cites W2886653651 @default.
• W4323036081 cites W2889014405 @default.
• W4323036081 cites W2889801464 @default.
• W4323036081 cites W2894350218 @default.
• W4323036081 cites W2897236707 @default.
• W4323036081 cites W2903807227 @default.
• W4323036081 cites W2921448113 @default.
• W4323036081 cites W2938589827 @default.
• W4323036081 cites W2945915427 @default.
• W4323036081 cites W2947893479 @default.
• W4323036081 cites W2990351859 @default.
• W4323036081 cites W2991218841 @default.
• W4323036081 cites W3023631620 @default.
• W4323036081 cites W3023967508 @default.
• W4323036081 cites W3044164917 @default.
• W4323036081 cites W3047507222 @default.
• W4323036081 cites W3080743922 @default.
• W4323036081 cites W3089634467 @default.
• W4323036081 cites W3112030517 @default.
• W4323036081 cites W3132107456 @default.
• W4323036081 cites W3153945848 @default.
• W4323036081 cites W3158318954 @default.
• W4323036081 cites W3191534679 @default.
• W4323036081 cites W3210734597 @default.
• W4323036081 cites W4206841660 @default.
• W4323036081 cites W4213004412 @default.
• W4323036081 cites W4225533139 @default.
• W4323036081 cites W4281752578 @default.
• W4323036081 cites W4293778942 @default.
• W4323036081 cites W4304630351 @default.
• W4323036081 cites W647183827 @default.
• W4323036081 doi "https://doi.org/10.1007/s00259-023-06165-9" @default.
• W4323036081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36864360" @default.
• W4323036081 hasPublicationYear "2023" @default.
• W4323036081 type Work @default.
• W4323036081 citedByCount "4" @default.
• W4323036081 countsByYear W43230360812023 @default.
• W4323036081 crossrefType "journal-article" @default.
• W4323036081 hasAuthorship W4323036081A5008293723 @default.
• W4323036081 hasAuthorship W4323036081A5010463928 @default.
• W4323036081 hasAuthorship W4323036081A5029014575 @default.
• W4323036081 hasAuthorship W4323036081A5035484134 @default.
• W4323036081 hasAuthorship W4323036081A5045912194 @default.
• W4323036081 hasAuthorship W4323036081A5048456616 @default.
• W4323036081 hasAuthorship W4323036081A5050744570 @default.
• W4323036081 hasAuthorship W4323036081A5057397331 @default.
• W4323036081 hasAuthorship W4323036081A5063488694 @default.
• W4323036081 hasAuthorship W4323036081A5066767510 @default.
• W4323036081 hasAuthorship W4323036081A5067342192 @default.
• W4323036081 hasAuthorship W4323036081A5070642253 @default.
• W4323036081 hasBestOaLocation W43230360811 @default.
• W4323036081 hasConcept C121608353 @default.
• W4323036081 hasConcept C126322002 @default.
• W4323036081 hasConcept C143998085 @default.
• W4323036081 hasConcept C2776551883 @default.
• W4323036081 hasConcept C2776907518 @default.
• W4323036081 hasConcept C2780192828 @default.
• W4323036081 hasConcept C2781190966 @default.
• W4323036081 hasConcept C3019894029 @default.
• W4323036081 hasConcept C61367390 @default.
• W4323036081 hasConcept C71924100 @default.
• W4323036081 hasConceptScore W4323036081C121608353 @default.
• W4323036081 hasConceptScore W4323036081C126322002 @default.

• next